A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04182204 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Rituximab
DRUG: Gemcitabine
DRUG: Oxaliplatin

Sponsor

Hoffmann-La Roche